Ketamine+betaine microneedle patch - PharmaTher
Alternative Names: KETABET™; KETABET™ MN patch; ketamine+betaine anhydrous - PharmaTher; KETAPATCHTMLatest Information Update: 28 Mar 2025
At a glance
- Originator National Health Research Institutes
- Developer PharmaTher
- Class Analgesics; Antidepressants; Cyclohexanes; General anaesthetics; Quaternary ammonium compounds; Small molecules; Trimethyl ammonium compounds
- Mechanism of Action AMPA receptor agonists; Methyltransferase stimulants; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Depressive disorders; Neuropathic pain; Postoperative pain
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Depressive disorders in Canada (Transdermal, Patch)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Neuropathic-pain in Canada (Transdermal, Patch)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Postoperative-pain in Canada (Transdermal, Patch)